# Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Source: https://onco.cc/trials/nct04145622/  
OnCo record `nct04145622` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ifinatamab deruxtecan in advanced solid tumours, run by Daiichi Sankyo, now recruiting.

## Summary

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors is a phase 1/2 interventional study registered as NCT04145622 by Daiichi Sankyo, with 250 participants planned, started 2019-11-03 and due to reach its primary completion in 2027-04-30. Interventions recorded: Ifinatamab deruxtecan (I-DXd).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04145622
- Phase: 1/2
- Setting: Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)
- Sponsor: Daiichi Sankyo
- Enrolled: 250

## Sources

- ClinicalTrials.gov NCT04145622: https://clinicaltrials.gov/study/NCT04145622

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04145622.json